A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going […]
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
What are embryonic stem cells and how do we scientists obtain them? My lab here at UC Davis School of Medicine has been doing research on embryonic stem cells for more than 14 years. You’ve come to the right place for expert answers on these very intriguing cells. What’s in this article Where do embryonic
What are embryonic stem cells & where do they come from? Read More »
Induced pluripotent stem cells or iPS cells just might be the most exciting development in the stem cell field over the last 15 years. They have unique potential for clinical impact for regenerative medicine too. This may manifest both through their use to produce differentiated cellular therapies and indirectly via disease modeling as well as
What are induced pluripotent stem cells or IPS cells? Read More »
In any given field of biomedical science like stem cell research and regenerative medicine, it’s very useful if you can accurately predict the future. It seems, though, that predictions are far more difficult within the more exciting and rapidly-changing fields. The field of stem cells and regenerative medicine fits that bill. Past stem cell research
21 Stem Cell Research & Regenerative Medicine 2021 Predictions Read More »
IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for
Overview of IPS cell prospects for clinical impact Read More »
The FDA has stem cell clinics squarely on its radar screen now and it’s pulling the trigger with many letters going out to this problematic industry. In the past, sometimes years went by with no letters at all or one letter in total to stem cell clinics so this marks a major shift. Background on
Historic spring storm of FDA letters to stem cell clinic industry Read More »
Masayo Takahashi is a leading stem cell researcher doing translational and clinical research on vision. She’s doing pioneering work on using pluripotent stem cells as a basis for helping patients with vision loss such as due to macular degeneration. She won The Niche’s Stem Cell Person of the Year Award in 2014 and a number
Masayo Takahashi (高橋 政代): exciting vision work advancing including with photoreceptors Read More »
The NIH announced the launch of the 1st autologous induced pluripotent stem (IPS) cell trial for vision loss in the U.S., focused on macular degeneration. The protocol is based on a solid foundation of pre-clinical animal studies: “Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a
1st autologous IPS cell clinical trial for vision loss in the US Read More »
ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the
ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »
Back in 2013, a half dozen years ago, I went out on a limb and made predictions for the stem cell field for 2020. These are different than my yearly predictions for the coming year (for instance, you can see my predictions made in 2018 for this year of 2019 here). As to my 2013
7-Year Glitch? Updates on my overly optimistic 2013 stem cell predictions for 2020 Read More »